111 Inc – Is Stock ADR (YI) at the top of the pharmaceutical retail industry?


111 Inc – ADR (YI) is at the top of the pharmaceutical retail industry according to InvestorsObserver. YI received an overall rating of 49, meaning it scores above 49% of all actions. 111 Inc – ADR also scored 85 in the pharma retailer industry, putting it above 85% of pharma retailer stocks. Pharmaceutical retailers are ranked 137 out of 148 industries.

YI has an overall score of 49. Find out what this means for you and get the rest of the rankings on YI!

What do these notes mean?

Stock analysis can be difficult. There are tons of numbers and ratios out there, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We categorize most of our scores by percentiles to make it easier for investors to understand. A score of 49 means the stock is more attractive than 49% of stocks. These rankings allow you to easily compare stocks and see what the strengths and weaknesses of a given company are. This allows you to find the stocks with the best short-term and long-term growth prospects in seconds. The combined score incorporates technical and fundamental analysis to provide a comprehensive view of a stock’s performance. Investors who then want to focus on analyst rankings or valuations can view separate scores for each section.

What’s going on with 111 Inc – ADR Stock today?

111 Inc – ADR (YI) stock is flat at 0% while the S&P 500 is down -1.54% at 11:03 a.m. Friday, August 26. YI is unchanged $0.00 from the previous closing price of $2.71 on volume of 101,544 shares. Over the past year, the S&P 500 has fallen -7.51% while the YI is -59.25% lower. YI has lost -$1.11 per share over the past 12 months. Click here for the full stock report for 111 Inc – ADR stock.

Stay in the know

Subscribe to our daily morning update newsletter and never miss market news, moves and more.

Thank you for signing up! You are ready to receive the Morning Update newsletter


Comments are closed.